Hongbo Lu
CIK: 0001767584
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (20 total)
- Jun 15, 2026ZBIO
Zenas BioPharma, Inc.
Award(A)DirectStock Option (Right to Buy)
18.5K shares- - May 12, 2026ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Sale(S)Direct3K shares at avg. $76.88$228K - Mar 31, 2026ZBIO
Zenas BioPharma, Inc.
Purchase(P)Indirect3.8K shares at avg. $18.63$70K - Feb 11, 2026ZBIO
Zenas BioPharma, Inc.
Purchase(P)Indirect26K shares at avg. $22.50$585K - Dec 16, 2025ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Award(A)Direct7.8K shares- - Oct 7, 2025ZBIO
Zenas BioPharma, Inc.
Purchase(P)Indirect263.2K shares at avg. $19.00$5.0M - Jun 11, 2025TERN
Terns Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
45K shares- - Jun 10, 2025ZBIO
Zenas BioPharma, Inc.
Award(A)DirectStock Option (Right to Buy)
18.5K shares- - Feb 1, 2025TERN
Terns Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
10.7K shares- - Dec 18, 2024ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Award(A)Direct16.7K shares at avg. $22.99$385K - Sep 25, 2024ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Gift(G)Direct5.7K shares- - Sep 13, 2024ZBIO
Zenas BioPharma, Inc.
Purchase(P)Indirect58.8K shares at avg. $17.00$1000K - Sep 12, 2024TERN
Terns Pharmaceuticals, Inc.
Purchase(P)Indirect285.7K shares at avg. $10.50$3.0M - Sep 12, 2024TERN
Terns Pharmaceuticals, Inc.
Purchase(P)Indirect190.5K shares at avg. $10.50$2.0M - Sep 12, 2024ZBIO
Zenas BioPharma, Inc.
Award(A)DirectStock Option (Right to Buy)
37K shares- - Apr 18, 2024ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Purchase(P)Direct500 shares at avg. $22.00$11K - Apr 10, 2024ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Purchase(P)Direct500 shares at avg. $25.00$13K - Apr 2, 2024ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Purchase(P)Direct150 shares at avg. $27.34$4K - Mar 26, 2024ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Purchase(P)Direct850 shares at avg. $27.50$23K - Mar 22, 2024ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Purchase(P)Direct400 shares at avg. $28.00$11K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 15, 2026 |  ZBIO Zenas BioPharma, Inc. | Award(A) Stock Option (Right to Buy) | 18,500 | - | - | Direct |
| May 12, 2026 |  ARWR ARROWHEAD PHARMACEUTICALS, INC. | Sale(S) | 2,970 | $76.88 | $228,334 | Direct |
| Mar 31, 2026 | ZBIO Zenas BioPharma, Inc. | Purchase(P) | 3,768 | $18.63 | $70,198 | Indirect |
| Feb 11, 2026 | ZBIO Zenas BioPharma, Inc. | Purchase(P) | 25,985 | $22.50 | $584,663 | Indirect |
| Dec 16, 2025 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Award(A) | 7,819 | - | - | Direct |
| Oct 7, 2025 | ZBIO Zenas BioPharma, Inc. | Purchase(P) | 263,160 | $19.00 | $5,000,040 | Indirect |
| Jun 11, 2025 |  TERN Terns Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 45,000 | - | - | Direct |
| Jun 10, 2025 | ZBIO Zenas BioPharma, Inc. | Award(A) Stock Option (Right to Buy) | 18,500 | - | - | Direct |
| Feb 1, 2025 | TERN Terns Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 10,657 | - | - | Direct |
| Dec 18, 2024 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Award(A) | 16,733 | $22.99 | $384,692 | Direct |
| Sep 25, 2024 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Gift(G) | 5,650 | - | $0 | Direct |
| Sep 13, 2024 | ZBIO Zenas BioPharma, Inc. | Purchase(P) | 58,823 | $17.00 | $999,991 | Indirect |
| Sep 12, 2024 | TERN Terns Pharmaceuticals, Inc. | Purchase(P) | 285,714 | $10.50 | $2,999,997 | Indirect |
| Sep 12, 2024 | TERN Terns Pharmaceuticals, Inc. | Purchase(P) | 190,476 | $10.50 | $1,999,998 | Indirect |
| Sep 12, 2024 | ZBIO Zenas BioPharma, Inc. | Award(A) Stock Option (Right to Buy) | 37,000 | - | - | Direct |
| Apr 18, 2024 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Purchase(P) | 500 | $22.00 | $11,000 | Direct |
| Apr 10, 2024 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Purchase(P) | 500 | $25.00 | $12,500 | Direct |
| Apr 2, 2024 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Purchase(P) | 150 | $27.34 | $4,101 | Direct |
| Mar 26, 2024 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Purchase(P) | 850 | $27.50 | $23,375 | Direct |
| Mar 22, 2024 | ARWR ARROWHEAD PHARMACEUTICALS, INC. | Purchase(P) | 400 | $28.00 | $11,200 | Direct |
1-20 of 20 transactions
About Lu Hongbo
Lu Hongbo (SEC CIK 0001767584) files insider reports with the SEC as Director of Zenas BioPharma, Inc. (ZBIO), Director of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) and Director of Terns Pharmaceuticals, Inc. (TERN).
Signal8 holds 15 ownership filings by Lu Hongbo (1 Form 3, 13 Form 4, 1 Form 5), filed between Sep 12, 2024 and Jun 17, 2026. Those filings report 20 transactions, from Mar 22, 2024 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lu Hongbo's filings is in PASADENA, CA.
Recent filings by Lu Hongbo
- Jun 15, 2026: Grant or award of ZBIO derivative securities (Form 4, code A).
- May 12, 2026: Open-market sale of ARWR shares (Form 4, code S).
- Mar 31, 2026: Open-market purchase of ZBIO shares (Form 4, code P).
- Feb 11, 2026: Open-market purchase of ZBIO shares (Form 4, code P).
- Dec 16, 2025: Grant or award of ARWR shares (Form 4, code A).
Other insiders filing for Zenas BioPharma, Inc. (ZBIO)
- InnoCare Pharma Inc., 10% Owner
- Oliger Christy J., Director
- Nunn Jason Raleigh, Director
- MOULDER LEON O JR
- ORLOFF JOHN J, Director
- von Moltke Lisa